Follow us on Twitter
twitter icon@FreshPatents


Polynucleotide patents

      

This page is updated frequently with new Polynucleotide-related patent applications.




 Method for attaching one or more polynucleotide binding proteins to a target polynucleotide patent thumbnailMethod for attaching one or more polynucleotide binding proteins to a target polynucleotide
The invention relates to new methods of attaching one or more polynucleotide binding proteins to a target polynucleotide. The invention also relates to new methods of characterising target polynucleotides..
Oxford Nanopore Technologies Ltd.


 Drug-inducible promoter and  inducting gene expression using the same patent thumbnailDrug-inducible promoter and inducting gene expression using the same
This invention provides a drug-inducible promoter that can be used for sugarcane plants and plants related thereto. Such drug-inducible promoter comprises a polynucleotide comprising a first nucleotide sequence having 90% or higher identity to the nucleotide sequence as shown in seq id no: 1, a second nucleotide sequence having 90% or higher identity to the nucleotide sequence as shown in seq no: 2, a third nucleotide sequence having 90% or higher identity to the nucleotide sequence as shown in seq id no: 3, a fourth nucleotide sequence having 90% or higher identity to the nucleotide sequence as shown in seq id no: 4, and a fifth nucleotide sequence having 90% or higher identity to the nucleotide sequence as shown in seq id no: 5 in such an order from the 3 terminal side toward the 5′ terminal side..
Toyota Jidosha Kabushiki Kaisha


 Bispecific chimeric antigen receptors and encoding polynucleotides thereof patent thumbnailBispecific chimeric antigen receptors and encoding polynucleotides thereof
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain fv (scfv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors..
Seattle Children's Hospital D/b/a Seattle Children's Research Institute


 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics patent thumbnailPolypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against krtcap3, fam26f, mgc52498, fam70a or tmem154 antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages.
Compugen Ltd


 Antibodies to hgf and compositions containing patent thumbnailAntibodies to hgf and compositions containing
The present invention is directed to antibodies and fragments thereof having binding specificity for hgf. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Alderbio Holdings Llc


 Haemophilus influenzae type iv pili patent thumbnailHaemophilus influenzae type iv pili
The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.
Nationwide Children's Hospital, Inc.


 Pap peptide analogues patent thumbnailPap peptide analogues
The application provides a polypeptide comprising the sequence slmtnlaal, ser 13 to leu 21 of amino acid sequence shown in fig. 1 or seq id no 1, and having hla-a2 haplotype binding activity, or a polynucleotide encoding said polypeptide.
The Nottingham Trent University


 Methods and compositions for the quantitation of mitochondrial nucleic acid patent thumbnailMethods and compositions for the quantitation of mitochondrial nucleic acid
Provided herein are products and processes for the quantitation of mitochondrial nucleic acid in a sample from a subject. In certain aspects are multiplex methods for determining dosage of mitochondrial nucleic acid relative to genomic nucleic acid for a sample from a subject including amplifying sets of mitochondrial polynucleotides and genomic polynucleotides from nucleic acid for a sample under amplification conditions.
Agena Bioscience, Inc.


 Systems and methods for substrate enrichment patent thumbnailSystems and methods for substrate enrichment
A method of separating bead substrates includes applying an emulsion to an emulsion-breaking solution. A dispersed phase of the emulsion includes an unbound polynucleotide, a first set of bead substrates and a second set of bead substrates.
Life Technologies Corporation


 Polynucleotides and polypeptides in plants patent thumbnailPolynucleotides and polypeptides in plants
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
Mendel Biotechnology, Inc.


Dna vectors, transposons and transposases for eukaryotic genome modification

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression.
Dna2.0, Inc.

Dna vectors, transposons and transposases for eukaryotic genome modification

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression.
Dna2.0, Inc.

Variants of gh family 11 xylanase and polynucleotides encoding same

The present invention relates to gh family 11 xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Dna vectors, transposons and transposases for eukaryotic genome modification

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression.
Dna2.0, Inc.

Dna vectors, transposons and transposases for eukaryotic genome modification

The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression.
Dna2.0, Inc.

Methods for reprogramming cells and uses thereof

A method of obtaining a cardiac multipotent or unipotent cell, comprising: i) providing a cell of a first type which is not a cardiac multipotent or unipotent cell; ii) introducing into the cell of a first type an agent capable of remodeling the chromatin and/or dna of the cell, wherein the agent capable of remodeling the chromatin and/or dna is a histone acetylator, an inhibitor of histone deacetylation, a dna demethylator, and/or a chemical inhibitor of dna methylation; iii) introducing into the cell of a first type a reprogramming polypeptide and/or a polynucleotide encoding said reprogramming polypeptide, wherein the reprogramming polypeptide comprises mesp1, brachyury (t), nkx2.5, and/or tbx5; and iv) placing or maintaining the cell in a cardiac cell culture medium and maintaining intracellular levels of the reprogramming polypeptide or the polynucleotide encoding the reprogramming polypeptide for a sufficient period of time to allow a cardiac multipotent or unipotent cell to be obtained.. .
Genesis Technologies Limited

Anti-blys antibodies

The present invention provides antibodies and antigen-binding fragments thereof that bind specifically to blys, immunoglobulin chains thereof, variants thereof; and method of use thereof, e.g., for the treatment or prevention of inflammatory and/or immune diseases such as systemic lupus erythramatous; as well as polynucleotides encoding the immunoglobulin chains of such antibodies and fragments. Methods for the recombinant expression of immunoglobulin chains are also part of the present invention..

Toxin genes and methods for their use

Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided.
Athenix Corporation

Automated pipetting apparatus having a combined liquid pump and pipette head system

The technology described herein generally relates to systems for extracting polynucleotides from multiple samples, particularly from biological samples, and additionally to systems that subsequently amplify and detect the extracted polynucleotides. The technology more particularly relates to microfluidic systems that carry out pcr on multiple samples of nucleotides of interest within microfluidic channels, and detect those nucleotides.
Handylab, Inc.

Methods and compositions for enhanced production of fatty aldehydes and fatty alcohols

The invention relates to the use of entd polypeptides, polynucleotides encoding the same, and homologues thereof to enhance the production of fatty aldehydes and fatty alcohols in a host cell.. .
Reg Life Sciences, Llc

Xylanase variants and polynucleotides encoding same

The present invention relates to xylanase variants, comprising an alteration at least at one position corresponding to position 87 of the polypeptide of seq id no: 3, wherein the variant has xylanase activity and has increased xylanase inhibitor tolerance compared to the xylanase of seq id no: 3; and i) wherein the variant has at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, but less than 100% sequence identity to the polypeptide of seq id no: 3; or ii) wherein the number of alterations is 1-20, e.g., 1-10 such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Coagulation factor vii polypeptides

The present invention relates to modified coagulation factor vii polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment..
Novo Nordisk Healthcare Ag

Alpha-amylase variants and polynucleotides encoding same

The present invention relates to alpha-amylase variants with improved stability in the presence of glucose and/or relatively higher activity on long chain versus short chain substrates. The present encoding invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Polypeptides having phospholipase c activity and polynucleotides encoding same

The present invention provides polypeptides having phospholipase c activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides.
Novozymes A/s

Polypeptides having phospholipase c activity and polynucleotides encoding same

The present invention relates to a method of reducing the phospholipid content in an oil or fat composition and polypeptides having pi-specific phospholipase c activity as well as polypeptides having pc, pe-specific phospholipase c activity and combinations thereof capable of catalyzing this reduction. The invention also relates to polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Diblock copolymers and polynucleotide complexes thereof for delivery into cells

Described herein are copolymers, and methods of making and utilizing such copolymers. Such copolymers have at least two blocks: a first block that has at least one unit that is hydrophilic at physiologic ph, and a second block that has hydrophobic groups.
Phaserx, Inc.

Bispecific t cell activating antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for t cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides.
Hoffmann-la Roche Inc.

Polypeptide structural motifs associated with cell signaling activity

Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and fragments of such polypeptides, etc., as well as compositions and methods of identifying and using any of the foregoing..
Atyr Pharma, Inc.

Bispecific t cell activating antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for t cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides.
Hoffmann-la Roche Inc.

Homogeneous preparations of il-31

Homogeneous preparations of human and murine il-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity..
Zymogenetics, Inc.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Nucleic acid adaptors and uses thereof

Provided herein are compositions, systems, methods, and kits for joining together the ends of one or more polynucleotides using at least one pair of blocking oligonucleotide adaptors. Blocking oligonucleotide adaptors can be used to reduce the formation of adaptor dimers or trimers (or higher-order concatemers) which can improve the yield of desirable polynucleotide-adaptor products in any recombinant nucleic acid workflow.
Life Technologies Corporation

Transaminase biocatalysts

The present disclosure relates to polypeptides having transaminase activity, polynucleotides encoding the polypeptides, and methods of using the polypeptides.. .
Codexis, Inc.

Recombinant host cells comprising phosphoketalase

The present invention is related to recombinant host cells comprising: (i) at least one deletion, mutation, and/or substitution in an endogenous gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate or acetyl-coa; and (ii) a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. The present invention is also related to recombinant host cells further comprising (iii) a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity..
Butamax Advanced Biofuels Llc

Microrna compositions and methods for enhancing plant resistance to abiotic stress

A method of increasing tolerance of a plant to an abiotic stress or increasing biomass, vigor or yield of a plant is disclosed. The method comprising upregulating within the plant an exogenous polynucleotide of a microrna or a precursor thereof, wherein the microrna is selected from the group consisting of mir-156, mir-169, mir-164, mir-159, mir-167, mir-529, mir-168, ppt-mir395, sof-mir408a, ath-mir408, mir-1039, mir-1091, mir-1118, mir-1134 and mir-1129, thereby increasing the tolerance of the plant to the abiotic stress or increasing the biomass, vigor or yield of the plant..
A.b. Seeds Ltd.

Constructs and use for rice gluatamate receptor-like genes

Isolated polynucleotides and polypeptides, and recombinant dna constructs are useful for conferring drought tolerance and/or improved nitrogen use efficiency. Compositions (such as plants or seeds) comprise these recombinant dna constructs; and methods utilize these recombinant dna constructs.
Pioneer Overseas Corporation

Isolated polynucleotides, polypeptides and methods of using same for increasing abiotic stress tolerance, biomass and yield of plants

Provided are isolated polypeptides which are at least 80% homologous to seq id nos: 552-897 and 6029-10629, isolated polynucleotides which are at least 80% identical to seq id nos: 1-551 and 898-6028, nucleic acid constructs comprising same, transgenic cells expressing same, transgenic plants expressing same and method of using same for increasing yield, abiotic stress tolerance, growth rate, biomass, vigor, oil content, photosynthetic capacity, seed yield, fiber yield, fiber quality, fiber length, and/or nitrogen use efficiency of a plant.. .
Evogene Ltd.

Genetically modified fungi and their use in lipid production

The invention refers to fungal cells, and especially to oleaginous fungal cells that have been genetically modified to produce enzymes of the pyruvate dehydrogenase bypass route to enhance their lipid production. Especially the cells are modified to overexpress genes encoding pyruvate decarboxylase (pdc), acetaldehyde dehydrogenase (ald) and/or acetyl-coa synthetase (acs), optionally together with a gene encoding diacylglycerol acyltransferase (dat), or to express genes encoding pdc together with ald and/or acs.
Teknologian Tutkimuskeskus Vtt

Genetic correction of myotonic dystrophy type 1

The invention relates to polynucleotides suitable for reducing or eliminating the expression of expanded repeat rna (cugexp) of the dystrophy myotonic-protein kinase (dmpk) gene in a cell of a dm-1 patient. The polynucleotides are a combination of a polynucleotide for a site specific nuclease targeting the dystrophy myotonic-protein kinase (dmpk) gene locus, and a donor polynucleotide having 5′ and 3′ regions which are homologous with the sequence of dmpk gene which flank the target site of the nuclease.
The General Hospital Corporation

Novel immunoconjugates

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an fc domain and a single effector moiety.
Roche Glycart Ag

Agonistic antibodies specifically binding cd40 and methods of use

The present invention relates to agonistic antibodies specifically binding human cd40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.. .
Janssen Biotech, Inc.

Methods for treating osteoarthristis pain by administering a nerve growth factor antagonist and compositions containing the same

The invention concerns anti-ngf antibodies (such as anti-ngf antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain..
Rinat Neuroscience Corp.

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
Bristol-myers Squibb Company

Thermostable carbonic anhydrases and methods of use thereof

The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for use in extracting carbon dioxide..
Danisco Us Inc

Genetic detection platform

Disclosed herein are methods, compositions, assays, and kits for performing polynucleotide amplification utilizing a pure polynucleotide polymerase. Also disclosed herein are methods, compositions, assays, and kits for removal of nucleic acid contaminant from the polynucleotide polymerase..
Pharmozyme, Inc.

Polypeptides having peroxygenase activity

The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Polypeptides having peroxygenase activity

The present invention relates to isolated polypeptides having peroxygenase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Beta-glucanase variants and polynucleotides encoding same

The present invention relates to beta-glucanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Novel polypeptide binding to extracellular domain of epidermal growth factor receptor

The present invention relates to a polypeptide capable of binding specifically to the extracellular domain of epidermal growth factor receptor, a polynucleotide that encodes the polypeptide, an expression vector comprising the polynucleotide, a recombinant microorganism having the expression vector introduced therein, and a method of producing the polypeptide using the recombinant microorganism. The polypeptide according to the present invention can bind to the extracellular domain of epidermal growth factor receptor with a high binding affinity comparable to those of existing monoclonal antibodies that are widely used as targeted therapeutic agents, thereby inhibiting the activity of the epidermal growth factor receptor.
Korea Advanced Institute Of Science And Technology

Antibodies that bind colony stimulating factor 1 receptor (csf1r)

Antibodies that bind csf1r are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind csf1r are also provided.
Five Prime Therapeutics, Inc.

Peptides for preventing or treating bone diseases and use thereof

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation

Novel peptides for preventing or treating bone diseases and use thereof

The present disclosure relates to a novel peptide for preventing or treating bone diseases. Further, the present disclosure relates to a polynucleotide encoding the peptide, a vector including the polynucleotide, a host cell transformed by the vector, and a method for producing the peptide by using the host cell.
Kyungpook National University Industry - Academic Cooperation Foundation



Polynucleotide topics:
  • Nucleotide
  • Polynucleotide
  • Polypeptide
  • Antagonist
  • Nucleic Acid
  • Cancer Cell
  • Drug Resistance
  • Chromosome
  • Glycoprotein
  • Gastrointestinal
  • Gastrointestinal Stromal Tumors
  • Gastrointestinal Stromal Tumor
  • Cellobiohydrolase
  • Human Disease
  • Inflammation


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Polynucleotide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Polynucleotide with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.4821

    file did exist - 2847

    2 - 1 - 57